Company / Current Liabilities
Summit Therapeutics Inc. Current Liabilities History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$73.0M
FY2025
5-year range
$20.4M / $73.0M
FY2021-FY2025
Trend
+74.9%
vs FY2024
Sector context
#119 of 213
Health Care
What the data says
At $73M, Summit Therapeutics Inc.'s current liabilities ranks #95 of 213 in the Health Care sector. Increased from $20M to $73M over the past 2 years.
Based on SEC 10-K filings.
$73M in FY2025 with a 5-year CAGR of +29.7%.
Increased from $20M to $73M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +23.5%
- 5-Year CAGR
- +29.7%
- 10-Year CAGR
- -
Sector benchmark
#95 of 213 in Health CareTop 44% of 213This company $73.0M Sector average $1.6B
▼
-95.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +29.7%, indicating consistent growth.
- In FY2025, current liabilities increased 74.9% year-over-year.
- Ranks #119 out of 213 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $73.0M | +74.9% |
| FY2024 | $41.7M | +104.5% |
| FY2023 | $20.4M | -47.4% |
| FY2022 | $38.8M | +51.4% |
| FY2021 | $25.6M | +28.8% |
| FY2020 | $19.9M | +44.5% |
| FY2019 | $13.8M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026